Business · 11/09/2024Updated: 10/17/2026 · 1 min read
FDA Approves OPZELURA (ruxolitinib) for Rare Pediatric Disease Priority Review Voucher
Summary
The FDA has approved OPZELURA (ruxolitinib), a product that redeems a priority review voucher, following a review of its approval on September 21, 2021.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →